Health & Biotech
Check out the latest Drug Development news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Neurotech hits new milestone in Phase II/III autism trial after treating last patient
Stockhead TV
WTF with Race Oncology: Changing the chemo game
Health & Biotech
Neurotech to extend Phase 2/3 autism spectrum disorder trial to adults
Health & Biotech
Dimerix gains on China drug application approval
Health & Biotech
Paradigm Biopharmaceuticals is transforming the way we treat osteoarthritis
Health & Biotech
Dimerix receives $10.7 million upfront payment from Advanz Pharma
Health & Biotech
Race Oncology releases ‘striking’ interim Phase 2 AML trial results
Health & Biotech
Q+A: Neurotech’s Dr Thomas Duthy on commercialising NTI164 as a treatment for PANDAS/PANS
Health & Biotech
Paradigm jumps 20pc on positive Phase 2 trial osteoarthritis results, including ‘notable increase’ in cartilage thickness
Health & Biotech
Prescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conference
Health & Biotech
‘Remarkable outcome’: Paradigm achieves outstanding results in phase II osteoarthritis trial
Health & Biotech
Neurotech treatment looks to be making a difference in children with PANDAS/PANS in Phase I/II clinical trial
Health & Biotech
Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease
Health & Biotech
FDA approves commercial brand name for Dimerix’s kidney disease drug
News
ASX Small Caps and IPO Weekly Wrap: Sharks circle but not in Azure waters
Health & Biotech
With patient randomisation complete, Dimerix locks in Q1 2024 window for part 1 of its Phase 3 FSGS kidney disease trial outcome
Health & Biotech
Stock Insiders: Bioxyne acquires Breathe Life Sciences with consumer favourite brand Dr Watson
Health & Biotech
Dimerix receives approval for paediatric investigation plan in Europe
Health & Biotech
PharmAust begins Cohort 3 dosing in Phase 1/2 motor neurone disease trial
Health & Biotech
Dimerix raises $8.7 million to advance Phase 3 trial for kidney drug
Experts
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part 2
Health & Biotech
ASX Biotech Stocks: A big red kidney dialysis bus and Recce reduces SARS-CoV-2 in hamsters
Health & Biotech
Dimerix leading race to find treatment for slowing progression of kidney disease
Health & Biotech
ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents
Health & Biotech
PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
Prescient unveils latest big hitter CellPryme-A at prestigious Boston CAR-TCR meeting
Health & Biotech
Kazia says diversification is the key to drug development
Health & Biotech
Dimerix moves fast to patent DMX-700 after ‘important new drug discovery’
Health & Biotech
Race Oncology’s breakthrough in Zantrene offers huge market opportunity in chemotherapy
News
ASX Small Caps Lunch Wrap: Who else is feeling refreshed after the weekend?
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Health & Biotech
Wellnex shares take flight on epic GlaxoSmithKline deal
Health & Biotech
Prescient Therapeutics half-year update shows why it’s one of the most exciting cancer research companies on the ASX
Health & Biotech
Wellnex Life is shaping up as the next major growth story in health and wellness as revenues surge
Health & Biotech
Science journal Nature reveals decade-long remissions; sparks hope for curative potential of CAR-T treatment
Health & Biotech
Prescient is well funded as it looks to bring its novel OmniCAR T-cell therapy into clinical trials
Health & Biotech
New brand launches and an innovative inventory has Wellnex Life Top Gun in ‘22
Health & Biotech
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
Health & Biotech
Wellnex shares rise on Pharmacy Own launch under CH2 deal
Health & Biotech
Prescient bolsters board with experienced and leading figures in CAR-T therapy
Health & Biotech
Dr Boreham’s Crucible: 4 ASX stocks focused on a mind-altering $25 billion psilocybin market
Health & Biotech
Neuroscientific Biopharmaceuticals says EmtinB shows promise as a multiple sclerosis treatment
Health & Biotech
Health Kick: Prescient Therapeutics’ YTD share price soars +220% after progress in clinical studies and CAR-T platform
Stockhead TV
Q-Wrapz: Oriel Morrison interviews Roger Aston, executive chairman of PharmAust Ltd (ASX:PAA)
Stockhead TV
Q-Wrapz: Oriel Morrison interviews Roby Zomer, Managing Director of MGC Pharma (ASX:MXC)
Health & Biotech
PharmAust flags good news on key stability test for Monepantel treatment
Load More